Advances in CAR-T Therapy for Central Nervous System Tumors

Overview

Journal Biomark Res

Publisher Biomed Central

Date 2024 Nov 7

PMID 39506843

Authors

Delian Zhou

Xiaojian Zhu

Yi Xiao

Affiliations

Soon will be listed here.

Abstract

The application of chimeric antigen receptor T-cell therapy in central nervous system tumors has significantly advanced; however, challenges pertaining to the blood-brain barrier, immunosuppressive microenvironment, and antigenic heterogeneity continue to be encountered, unlike its success in hematological malignancies such as acute lymphoblastic leukemia and diffuse large B-cell lymphomas. This review examined the research progress of chimeric antigen receptor T-cell therapy in gliomas, medulloblastomas, and lymphohematopoietic tumors of the central nervous system, focusing on chimeric antigen receptor T-cells targeting antigens such as EGFRvIII, HER2, B7H3, GD2, and CD19 in preclinical and clinical studies. It synthesized current research findings to offer valuable insights for future chimeric antigen receptor T-cell therapeutic strategies for central nervous system tumors and advance the development and application of this therapeutic modality in this domain.

References

Meister H, Look T, Roth P, Pascolo S, Sahin U, Lee S . Multifunctional mRNA-Based CAR T Cells Display Promising Antitumor Activity Against Glioblastoma. Clin Cancer Res. 2022; 28(21):4747-4756. DOI: 10.1158/1078-0432.CCR-21-4384. View

Maude S, Laetsch T, Buechner J, Rives S, Boyer M, Bittencourt H . Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. N Engl J Med. 2018; 378(5):439-448. PMC: 5996391. DOI: 10.1056/NEJMoa1709866. View

Peng J, Wang L, Li Z, Ku C, Ho P . Metabolic challenges and interventions in CAR T cell therapy. Sci Immunol. 2023; 8(82):eabq3016. DOI: 10.1126/sciimmunol.abq3016. View

Zhang Z, Xu Q, Huang L . B cell depletion therapies in autoimmune diseases: Monoclonal antibodies or chimeric antigen receptor-based therapy?. Front Immunol. 2023; 14:1126421. PMC: 9968396. DOI: 10.3389/fimmu.2023.1126421. View

Hubner J, Raschke M, Rutschle I, Grassle S, Hasenberg T, Schirrmann K . Simultaneous evaluation of anti-EGFR-induced tumour and adverse skin effects in a microfluidic human 3D co-culture model. Sci Rep. 2018; 8(1):15010. PMC: 6177413. DOI: 10.1038/s41598-018-33462-3. View

Beard R, Zheng Z, Lagisetty K, Burns W, Tran E, Hewitt S . Multiple chimeric antigen receptors successfully target chondroitin sulfate proteoglycan 4 in several different cancer histologies and cancer stem cells. J Immunother Cancer. 2014; 2:25. PMC: 4155770. DOI: 10.1186/2051-1426-2-25. View

Alsouqi A, Ahmed G, Wang J, Cassanello G, Szabo A, Rojek A . Chimeric antigen receptor T-cell therapy in secondary central nervous system lymphoma: A multicenter analysis. Am J Hematol. 2024; 99(8):1624-1627. DOI: 10.1002/ajh.27354. View

Gonzalez-Tablas Pimenta M, Otero A, Arandia Guzman D, Pascual-Argente D, Ruiz Martin L, Sousa-Casasnovas P . Tumor cell and immune cell profiles in primary human glioblastoma: Impact on patient outcome. Brain Pathol. 2020; 31(2):365-380. PMC: 8018082. DOI: 10.1111/bpa.12927. View

Krenciute G, Prinzing B, Yi Z, Wu M, Liu H, Dotti G . Transgenic Expression of IL15 Improves Antiglioma Activity of IL13Rα2-CAR T Cells but Results in Antigen Loss Variants. Cancer Immunol Res. 2017; 5(7):571-581. PMC: 5746871. DOI: 10.1158/2326-6066.CIR-16-0376. View

10.

Guo X, Chang M, Wang Y, Xing B, Ma W . B7-H3 in Brain Malignancies: Immunology and Immunotherapy. Int J Biol Sci. 2023; 19(12):3762-3780. PMC: 10411461. DOI: 10.7150/ijbs.85813. View

11.

Vora P, Venugopal C, Salim S, Tatari N, Bakhshinyan D, Singh M . The Rational Development of CD133-Targeting Immunotherapies for Glioblastoma. Cell Stem Cell. 2020; 26(6):832-844.e6. DOI: 10.1016/j.stem.2020.04.008. View

12.

Guzman G, Pellot K, Reed M, Rodriguez A . CAR T-cells to treat brain tumors. Brain Res Bull. 2023; 196:76-98. DOI: 10.1016/j.brainresbull.2023.02.014. View

13.

Pang N, Shi J, Qin L, Chen A, Tang Y, Yang H . IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelin. J Hematol Oncol. 2021; 14(1):118. PMC: 8323212. DOI: 10.1186/s13045-021-01128-9. View

14.

Nellan A, Rota C, Majzner R, Lester-McCully C, Griesinger A, Mulcahy Levy J . Durable regression of Medulloblastoma after regional and intravenous delivery of anti-HER2 chimeric antigen receptor T cells. J Immunother Cancer. 2018; 6(1):30. PMC: 5925833. DOI: 10.1186/s40425-018-0340-z. View

15.

Frigault M, Dietrich J, Martinez-Lage M, Leick M, Choi B, DeFilipp Z . Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma. Blood. 2019; 134(11):860-866. PMC: 7022436. DOI: 10.1182/blood.2019001694. View

16.

Siddiqi T, Wang X, Blanchard M, Wagner J, Popplewell L, Budde L . CD19-directed CAR T-cell therapy for treatment of primary CNS lymphoma. Blood Adv. 2021; 5(20):4059-4063. PMC: 8945630. DOI: 10.1182/bloodadvances.2020004106. View

17.

Lin H, Liu C, Hu A, Zhang D, Yang H, Mao Y . Understanding the immunosuppressive microenvironment of glioma: mechanistic insights and clinical perspectives. J Hematol Oncol. 2024; 17(1):31. PMC: 11077829. DOI: 10.1186/s13045-024-01544-7. View

18.

Wu A, Wei J, Kong L, Wang Y, Priebe W, Qiao W . Glioma cancer stem cells induce immunosuppressive macrophages/microglia. Neuro Oncol. 2010; 12(11):1113-25. PMC: 3098021. DOI: 10.1093/neuonc/noq082. View

19.

Prapa M, Chiavelli C, Golinelli G, Grisendi G, Bestagno M, Di Tinco R . GD2 CAR T cells against human glioblastoma. NPJ Precis Oncol. 2021; 5(1):93. PMC: 8551169. DOI: 10.1038/s41698-021-00233-9. View

20.

Del Vecchio C, Giacomini C, Vogel H, Jensen K, Florio T, Merlo A . EGFRvIII gene rearrangement is an early event in glioblastoma tumorigenesis and expression defines a hierarchy modulated by epigenetic mechanisms. Oncogene. 2012; 32(21):2670-81. DOI: 10.1038/onc.2012.280. View